A new topical is being tested for psoriasis.
A newly synthesized nonsteroidal anti-inflammatory drug, benvitimod, is a safe and effective topical treatment for mild to moderate plaque psoriasis, according to phase 3 trial results.
There hasn’t been a breakthrough topical treatment since vitamin D analogs hit the market in the 1980s, said Jianzhong Zhang, MD, PhD, with the department of dermatology at Peking University People’s Hospital in Beijing, China.
Benvitimod is a first-in-class drug, but the mechanism of action is not yet fully understood, he told Medscape Medical News.
Dr Zhang presented the results of the study here at the American Academy of Dermatology Annual Meeting.
He and his colleagues tested benvitimod in a randomized, multicenter, placebo- and comparator-controlled trial of 686 patients. Participants were adults with mild to moderate psoriasis for at least 6 months, a Physician Global Assessment (PGA) score of 2 or higher (on a 6-point scale), and a body surface area (BSA) of less than 10%.
Read full article: New Topical for Mild to Moderate Psoriasis in the Works
|Read Full Article: New Topical for Mild to Moderate Psoriasis in the Works|